Brokerages predict that Danaher Co. (NYSE:DHR – Get Rating) will announce $7.55 billion in sales for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Danaher’s earnings. The highest sales estimate is $7.64 billion and the lowest is $7.50 billion. Danaher reported sales of $6.86 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 10.1%. The firm is scheduled to report its next earnings report before the market opens on Monday, January 1st.
On average, analysts expect that Danaher will report full year sales of $30.83 billion for the current fiscal year, with estimates ranging from $30.67 billion to $31.23 billion. For the next year, analysts anticipate that the business will post sales of $32.30 billion, with estimates ranging from $31.74 billion to $32.95 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Danaher.
Danaher (NYSE:DHR – Get Rating) last released its quarterly earnings data on Thursday, January 27th. The conglomerate reported $2.69 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.50 by $0.19. Danaher had a return on equity of 18.87% and a net margin of 21.84%. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $7.98 billion. During the same quarter in the prior year, the firm posted $2.08 earnings per share. The firm’s revenue was up 20.5% compared to the same quarter last year.
Shares of Danaher stock traded down $0.80 on Friday, hitting $274.27. 65,269 shares of the company’s stock traded hands, compared to its average volume of 2,966,544. Danaher has a one year low of $238.32 and a one year high of $333.96. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.43 and a quick ratio of 1.09. The company has a fifty day moving average of $279.26 and a two-hundred day moving average of $295.93. The company has a market capitalization of $196.20 billion, a price-to-earnings ratio of 31.93, a price-to-earnings-growth ratio of 1.30 and a beta of 0.78.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 29th. Investors of record on Friday, March 25th will be issued a $0.25 dividend. This is a boost from Danaher’s previous quarterly dividend of $0.21. This represents a $1.00 dividend on an annualized basis and a yield of 0.36%. The ex-dividend date of this dividend is Thursday, March 24th. Danaher’s dividend payout ratio (DPR) is currently 11.60%.
In related news, SVP Brian W. Ellis sold 5,365 shares of the firm’s stock in a transaction on Wednesday, February 2nd. The stock was sold at an average price of $293.99, for a total value of $1,577,256.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Joakim Weidemanis sold 20,508 shares of the firm’s stock in a transaction on Monday, January 31st. The stock was sold at an average price of $285.24, for a total value of $5,849,701.92. The disclosure for this sale can be found here. Company insiders own 11.20% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. D Orazio & Associates Inc. purchased a new position in shares of Danaher in the 3rd quarter valued at approximately $27,000. Maryland Capital Advisors Inc. purchased a new position in shares of Danaher in the fourth quarter worth $28,000. Dixon Hughes Goodman Wealth Advisors LLC purchased a new position in shares of Danaher in the fourth quarter worth $29,000. Lee Financial Co purchased a new position in shares of Danaher in the fourth quarter worth $30,000. Finally, Evolution Advisers Inc. purchased a new position in shares of Danaher in the fourth quarter worth $32,000. Institutional investors own 82.84% of the company’s stock.
Danaher Company Profile (Get Rating)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.
- Get a free copy of the StockNews.com research report on Danaher (DHR)
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.